A single arm open-label multicenter phase II study of 177Lu-DOTATATE radionuclide in adults with progressive or high-risk meningioma

Brief description of study

This single arm, open-label study will evaluate the efficacy of Lutathera (177Lu-DOTATATE) administered intravenously every 8 weeks for a total of 4 doses in patients with progressive WHO I-III or residual high-risk 68Ga-DOTATATE PET-MRI positive meningioma. 68Ga-DOTATATE MRI scans will be obtained before and 6 months after initiation of treatment .


Clinical Study Identifier: s18-00719
ClinicalTrials.gov Identifier: NCT03971461
Principal Investigator: Erik P. Sulman.
Other Investigators: Minerva A Utate, Fabio Ponzo, Tori A Yuen, Alexandra M. Miller, Mona P. Natwa, Sylvia Amor Tenefrancia Crispino, Kent P Friedman, Timothy Michael Shepherd, Marissa Barbaro, Maria Del Pilar Guillermo Prieto Eibl, Jonathan Tzu-l Yang.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.